Attributes influencing parental decision-making to receive the Tdap vaccine to reduce the risk of pertussis transmission to their newborn - outcome of a cross-sectional conjoint experiment in Spain and Italy.
Adult
Aged
Cross-Sectional Studies
Decision Making
Diphtheria-Tetanus-acellular Pertussis Vaccines
/ administration & dosage
Female
Health Knowledge, Attitudes, Practice
Humans
Infant, Newborn
Italy
Male
Middle Aged
Parents
/ psychology
Spain
Vaccination
/ psychology
Whooping Cough
/ prevention & control
Young Adult
Italy
Pertussis
Sawtooth software
Spain
adaptive choice-based conjoint questionnaire
adaptive discrete-choice experiment
cocooning
preferences
survey
vaccination
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
9
2
2019
medline:
29
2
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Pertussis vaccination of parents and household contacts ('cocooning') to protect newborn infants is an established strategy in many countries, although uptake may be low. Many aspects may influence such decision-making. We conducted a cross-sectional survey (NCT01890447) of households and other close contacts of newborns aged ≤6 months (or of expectant mothers in their last trimester) in Spain and Italy, using an adaptive discrete-choice experiment questionnaire. Aims were to assess the relative importance of attributes influencing vaccine adoption, and to estimate variation in vaccine adoption rates and the impact of cost on vaccination rates. Six hundred and fifteen participants (Spain, n = 313; Italy, n = 302) completed the survey. Of 144 available questionnaire scenarios, the most frequently selected (14% of respondents in both countries) were infant protection by household vaccination at vaccination center, recommendation by family physician and health authorities, with information available on leaflets and websites. The attribute with highest median relative importance was 'reduction in source of infection' in Spain (23.1%) and 'vaccination location' in Italy (18.8%). Differences between other attributes were low in both countries, with media attributes showing low importance. Over 80% of respondents indicated a definite or probable response to vaccine adoption (at no-cost) with estimated probability of adoption of 89-98%; applying vaccine costs (25€ per person) would reduce the probability of uptake by 7-20% in definite/probable respondents. Awareness of these determinants is helpful in informing Health Authorities and healthcare practitioners implementing a cocooning strategy for those populations where maternal immunization is not a preferred option.
Identifiants
pubmed: 30735474
doi: 10.1080/21645515.2019.1571890
pmc: PMC6605846
doi:
Substances chimiques
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080-1091Références
Pediatr Infect Dis J. 2015 Nov;34(11):1244-9
pubmed: 26322660
Epidemiology. 2012 Nov;23(6):852-60
pubmed: 23018969
Hum Vaccin Immunother. 2018;14(10):2358-2364
pubmed: 29688133
Vaccine. 2015 Jan 1;33(1):228-36
pubmed: 25444794
PLoS One. 2014 Aug 19;9(8):e104772
pubmed: 25136919
Vaccine. 2014 Dec 5;32(51):7000-7004
pubmed: 25454869
BMC Public Health. 2013 Jul 23;13:676
pubmed: 23875762
Vaccine. 2015 Apr 8;33(15):1791-6
pubmed: 25728321
Rev Epidemiol Sante Publique. 2017 Nov;65(6):389-395
pubmed: 29089164
Patient. 2015 Oct;8(5):373-84
pubmed: 25726010
Patient. 2017 Dec;10(6):687-700
pubmed: 28474295
PLoS One. 2016 Jun 02;11(6):e0155861
pubmed: 27253386
Vaccine. 2015 May 5;33(19):2213-2220
pubmed: 25825331
Pharmacoecon Open. 2019 Mar;3(1):55-69
pubmed: 29761340
Vaccine. 2010 Sep 24;28(41):6692-7
pubmed: 20708696
BMC Infect Dis. 2014 Jul 17;14:397
pubmed: 25037057
Vaccine. 2013 Aug 20;31(37):3972-8
pubmed: 23777954
Vaccine. 2013 Jan 11;31(4):618-25
pubmed: 23200883
Vaccine. 2018 Feb 8;36(7):969-978
pubmed: 29338877
Vaccine. 2018 Jan 29;36(5):736-743
pubmed: 29269158
Rheumatol Ther. 2017 Jun;4(1):167-182
pubmed: 28255898
Hum Vaccin Immunother. 2013 May;9(5):1142-5
pubmed: 23370334
Hum Vaccin Immunother. 2018;14(11):2748-2754
pubmed: 30199307
Pediatrics. 2015 Jun;135(6):e1475-82
pubmed: 25963002
MMWR Morb Mortal Wkly Rep. 2011 Oct 21;60(41):1424-6
pubmed: 22012116
Hum Vaccin Immunother. 2015;11(5):1165-72
pubmed: 25874807
Vaccine. 2017 May 9;35(20):2676-2684
pubmed: 28408120
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S221-S226
pubmed: 27838676
Infect Dis (Lond). 2018 Aug;50(8):625-633
pubmed: 29616584
Hum Vaccin Immunother. 2015;11(1):108-17
pubmed: 25483523
Clin J Am Soc Nephrol. 2013 Nov;8(11):1942-51
pubmed: 23929931
Clin Infect Dis. 2010 May 15;50(10):1339-45
pubmed: 20370464
Hum Vaccin Immunother. 2015;11(7):1744-7
pubmed: 25912733
BMC Health Serv Res. 2011 Sep 09;11:214
pubmed: 21906293
Patient. 2010 Dec 1;3(4):257-73
pubmed: 22273433
Vaccine. 2016 Sep 7;34(39):4744-4751
pubmed: 27523741
Enferm Infecc Microbiol Clin. 2013 Apr;31(4):240-53
pubmed: 23411362
Euro Surveill. 2010 Apr 22;15(16):
pubmed: 20429999
Pediatr Infect Dis J. 2015 Sep;34(9):e222-32
pubmed: 26376316
Int J Public Health. 2016 Sep;61(7):847-60
pubmed: 27488917
Med Mal Infect. 2016 Jun;46(4):188-93
pubmed: 27132209
BMC Infect Dis. 2013 Mar 26;13:151
pubmed: 23530907